Research programme: antibody-drug conjugates - Genmab/Seattle Genetics

Drug Profile

Research programme: antibody-drug conjugates - Genmab/Seattle Genetics

Alternative Names: HuMax-CD74-ADC

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Genmab; Seattle Genetics
  • Class Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Axl receptor tyrosine kinase inhibitors; Immunomodulators; Mitosis inhibitors; Thromboplastin inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors; Tumour protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours
  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (Parenteral)
  • 10 Sep 2014 Genmab and Seattle Genetics enter into additional antibody-drug conjugate collaboration
  • 18 Jul 2013 Preclinical trials in Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top